Clinical Research Directory

Inclusion Criteria: 1. Signed informed consent. 2. Male or female ≥18 years with biopsy-confirmed IgAN; eGFR ≥30 mL/min/1.73 m² for main cohort; \>40 mL/min/1.73 m² for optional biopsy cohort. 3. Screening UPCR ≥0.5 g/g measured by first morning void. 4. Maximally tolerated or locally approved maximal ACEi/ARB dose before enrollment; diuretics, other antihypertensives and SGLT2i, if used, stabilized for at least 90 days before baseline. 5. WOCBP and sexually active participants must comply with protocol contraception requirements. Exclusion Criteria: 1. Hypersensitivity to study treatment/excipients or similar drug classes. 2. CKD primarily attributable to non-IgAN etiology. 3. Suspected RPGN or IgA vasculitis. 4. Nephrotic syndrome. 5. BNP \>200 pg/mL or NT-proBNP \>450 pg/mL at screening. 6. Platelets \<80,000/µL. 7. Organ transplant history other than corneal transplant. 8. Systemic immunosuppressants \>2 weeks in prior 3 months or rituximab within 6 months. 9. Confirmed BP \>150/95 mmHg based on mean of 3 screening measurements. 10. Heart failure/fluid overload. 11. Significant liver disease or transaminases/bilirubin \>2× ULN. 12. Hemoglobin \<9 g/dL or transfusion for anemia within 3 months. 13. Malignancy unless protocol-defined exception. 14. Pregnancy/breastfeeding or intent to become pregnant. 15. Male intent to father a child/donate sperm during study and 1 month after. 16. Recent investigational/approved IgAN treatment per protocol washout. 17. Clinically significant unstable/uncontrolled medical disorder that may confound results or add risk. 18. Alcohol/illicit drug-related disorder within 3 years. 19. WOCBP not using highly effective contraception; sexually active males unwilling to use condoms. 20. Prohibited therapies. 21. MRI contraindications. 22. Optional biopsy cohort exclusion if biopsy risk is unacceptably high.